Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial
Bruno François(Inserm), Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Sébastien Gibot(Centre Hospitalier Régional et Universitaire de Nancy), Marc Derive, Aurélie Olivier, Thierry Dugernier(Clinique Saint Pierre), Jean–Jacques Garaud, Xavier Wittebole(Cliniques Universitaires Saint-Luc), Valérie Cuvier, Margarita Salcedo‐Magguilli(Délégation Paris 7), Jean‐Paul Mira(Hôpital Cochin), Miguel Sánchez(Stellenbosch University), Stephan Witte(MerLion Pharma (Germany)), Peter Pickkers(Radboud University Nijmegen), François Vandenhende, Ricard Ferrer(Universitat Autònoma de Barcelona)
Cited by 71
Related Papers
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Intensive Care Medicine|2017|6.8k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
|Intensive Care Medicine|2021|5.1k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Critical Care Medicine|2017|3.8k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021
|Critical Care Medicine|2021|2.8k